136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
You may also be interested in...
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.
The German group is investing heavily in R&D and the continued strong performance of products like Spiriva and Pradaxa is helping to pay for future innovation.
Boehringer Ingelheim will increasingly use external collaborations in its search for new treatment options for neuropsychiatric diseases, its CNS R&D head tells Scrip.